Fish oil could help prevent type 2 diabetes mellitus in people with metabolic disorders
Type 2 diabetes mellitus (DM2) is currently one of the most common chronic diseases and its prevalence is forecast to increase to over 250 million people by 2030.
Several meta-analyses conclude that consuming omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) reduces the risk of DM2. The results of a recent meta-analysis carried out by researchers at Chongqing Medical University on a end total of 17 randomised controlled studies (with 672 participants) consistently show that supplementation with fish oil can have beneficial effects on insulin sensitivity in people, at least, metabolic disorder, reducing the risk of insulin resistance by 47%. The authors found no differences between the various doses used; however, they did identify the optimum intervention period as between 4 and 12 weeks. The minimum is four weeks, as this is the time required for serum levels of PUFA to stabilise, and the maximum is 12 weeks, as longer interventions did not show any efficacy with regard to insulin sensitivity.
In people with metabolic disorders, these results support dietary consumption of n-3 LC-PUFA for periods of 4 to 12 weeks, with the aim of preventing the development of DM2.